The cell culture market is an important and growing industry in the biotechnology field. This market includes cell culture products and services used in research and development of therapeutic treatments, cell-based assays, and cell and gene therapy. This is a multi-billion dollar industry that is expected to grow rapidly over the coming years. The market is driven by increasing demand for new cell types, increased research activities and the development of new technologies
Clinical trials are a critical part of the medical research process. They are used to determine the safety and efficacy of treatments, medications, and new therapies. The clinical trials market is a complex and growing industry that is essential for the advancement of medical research.
Cell Culture Market is projected to reach USD 41.3 billion by 2026 from USD 22.8 billion in 2021, at a CAGR of 12.6 % between 2021 and 2026. The growth of this market is majorly driven by the growing awareness about the benefits of cell-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference for single-use technologies, the launch of advanced cell culture products, and the growing focus on personalized medicine. On the other hand, the high cost of cell biology research is restraining the growth of this market.
Request for assumptions how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=559
Drivers: Growing awareness about the benefits of cell-based vaccines
The growth in population, climate change, and increasing contact between humans and animals have increased the threat of new virus outbreaks. Influenza and COVID-19, for example, have proven unpredictable and recurring events that pose a significant economic and social burden. As of February 4, 2022, 386.55 million cases of COVID-19 were confirmed globally, including 5.71 million deaths, by the WHO. The increasing incidence of infectious diseases and the growing risk of pandemics are expected to drive vaccine demand worldwide. In the pharmaceutical industry, cell culture has become a prominent part of vaccine production. The cell culture technology has been used to produce vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox. Cell-based flu vaccines have also been approved for use in the US and many European countries. Increasing awareness of the benefits of cell culture-based vaccines, coupled with the regulatory approval of several cell culture-based vaccines worldwide, are the major factors that are expected to support the growth of the cell culture market during the forecast period.
Opportunities: Growing demand for 3D cell culture
3D cell cultures are gaining demand over 2D cell cultures due to multiple reasons. 2D cell culture methods involve growing cells on flat surfaces as 2D monolayers. However, these cells adhere only to cell culture vessels and attach only to cells at the periphery; this limits multi-dimensional cell cultures. Researchers have come up with 3D cell cultures to resolve these issues. These cultures have proven to be efficient in several studies of basic biological mechanisms, such as cell number monitoring, cell viability, cell proliferation, and cell morphology. Moreover, 3D cell cultures have greater stability and longer lifespans as compared to 2D cultures. The benefits of 3D cell cultures have attracted several players to invest in this field. In June 2020, Lonza and CELLINK collaborated to offer a 3D bioprinting solution designed to advance complete 3D cell culture workflows.
The global cell culture market is a consolidated market, with Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany) together accounting for ~60–65% of the global market.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559
The clinical trials market is largely dominated by large pharmaceutical companies, which have the resources to conduct large-scale trials. However, smaller companies are beginning to enter the market, taking advantage of new technologies to conduct more cost-effective trials.
The increasing use of technology and the development of new treatments has also had an effect on the clinical trials market. For example, the use of electronic medical records, remote patient monitoring, and mobile health apps has enabled clinical trials to be conducted more quickly and efficiently.
The clinical trials market is also being impacted by increasing regulation, which has changed the way trials are conducted and monitored. This has led to an increase in the number of clinical trial consultants, who advise trial sponsors on how to comply with regulatory requirements.
Overall, the clinical trials market is a complex and rapidly-evolving industry that is essential for the advancement of medical research. With the increasing use of technology, new treatments, and increased regulation, the market is expected to continue to grow in the coming years.
Recent Developments:
- In October 2021, Thermo Fisher Scientific Inc. (US) launched the Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, which supports the large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells.
- In September 2021, Cytiva expanded its manufacturing capacity for bioprocessing single-use consumables by launching 3 new manufacturing facilities in under ten months.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html
